Emerging biotechnology companies preparing for their first launch face an important organizational question:
What should we build internally, and what should we outsource?
There is no universal answer.
The right operating model depends on the market, company strategy, capital, product complexity and the capabilities that will create long-term enterprise value.
Start With Capabilities—Not Job Titles
Leadership should first identify what the business must be capable of doing.
Those capabilities may include:
- commercial strategy;
- Medical Affairs;
- market access;
- marketing;
- commercial operations;
- analytics;
- field execution;
- patient services;
- training;
- distribution management.
Only after defining those requirements should leadership determine which need permanent internal teams. Related: biotech commercial organization planning.
When Internal Capability Matters
Internal ownership is particularly important when a capability:
- drives strategic differentiation;
- contains critical institutional knowledge;
- requires continual cross-functional decision-making;
- directly influences company strategy;
- is expected to remain important across multiple assets.
Commercial leadership is an obvious example.
The strategic decisions shaping market opportunity, organization and launch should remain clearly owned by the company even when outside advisors contribute.
When Outsourcing Can Make Sense
External partners can be highly effective when:
- expertise is specialized;
- requirements are temporary;
- scale will change rapidly;
- internal hiring would create premature fixed cost;
- implementation capability is readily available externally.
The question should not be whether outsourcing is inherently better or worse.
The question should be whether the model gives the company the capability, control and flexibility it requires.
Beware of Outsourcing Strategy
Execution can be outsourced.
Accountability cannot.
An emerging company can use external agencies, research firms, vendors and service providers while retaining strong strategic ownership internally.
When too much strategy is effectively delegated to vendors, leadership can lose the integrated view required for commercialization. Related: first commercial launch planning and biotech commercial strategy.
Build for Today—and the Portfolio Ahead
Organization planning should also reflect future strategy.
A company launching one specialized product may require one model.
A company expecting multiple indications or several assets may justify building broader permanent capabilities.
Organizational investment should therefore reflect both the immediate launch and credible long-term requirements.
The Financial Dimension
Every internal hire creates ongoing cost.
Every outsourced activity creates both cost and dependency.
The correct financial comparison should include:
- personnel;
- benefits;
- recruiting;
- systems;
- infrastructure;
- management;
- agency fees;
- transition cost;
- vendor oversight.
The cheapest model on paper is not always the lowest-risk model.
A Better Decision Framework
For every commercial capability, ask:
- Is this strategically differentiating?
- How long will we need it?
- How frequently will the requirement change?
- What institutional knowledge should remain inside the company?
- What is the cost of being wrong?
That produces a much stronger organization than simply copying another company's launch structure.
Discuss Commercial Organization Strategy
Speak with PharmaKonsult about the capabilities, hiring sequence and operating model your first U.S. commercial organization actually requires.
